Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review - Takeaways - MDSpire

Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review

  • By

  • Daxia Cai

  • Jun Li

  • Qiyi Chen

  • Xingdong Cai

  • Feng Tian

  • Yanyan Zhu

  • Jingjing Cao

  • Jianhui Huang

  • Xiu Lan

  • Zhifeng Tian

  • Jianfei Tu

  • Yonghui Wang

  • June 18, 2026

  • 0 min

Share

  • 1

    Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer with poor prognosis and resistance to standard therapies.

  • 2

    A case study reported a patient with PSC who initially had multiple primary lung cancers, including adenosquamous carcinoma and adenocarcinoma.

  • 3

    Histological transformation to PSC occurred after treatment with afatinib, an EGFR-TKI, following radical surgical resection.

  • 4

    The patient achieved a durable complete response to combined immunochemotherapy, highlighting the potential efficacy of this treatment approach.

  • 5

    No consensus guidelines exist for PSC management, necessitating further research on treatment options, particularly for PD-L1-positive cases.

Original Source(s)

Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review

  • by Daxia Cai, Jun Li, Qiyi Chen, Xingdong Cai, Feng Tian, Yanyan Zhu, Jingjing Cao, Jianhui Huang, Xiu Lan, Zhifeng Tian, Jianfei Tu, Yonghui Wang

  • June 18, 2026

Related Content

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

Four-dimensional computed tomography ventilation imaging-guided radiotherapy planning in different techniques for lung cancer

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study